Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy

Journal of Controlled Release

Volumn 253, Issue , 2017, Pages 82-96

  Silva, Vera L ^a   Al Jamal, Wafa’ T ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cancer hypoxia; Nanomedicine; Targeted cancer therapy; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG THERAPY; ENZYME INHIBITION; GENE EXPRESSION; MACROPHAGES; MEDICAL NANOTECHNOLOGY; ONCOLOGY;

CANCER HYPOXIA; CLINICAL PRACTICES; HYPOXIA-INDUCIBLE FACTORS; TARGETED CANCER THERAPY; TARGETED THERAPEUTICS; TUMOR ASSOCIATED MACROPHAGES; TUMOR MICROENVIRONMENT; TUMOR PROGRESSIONS;

TUMORS;

ANTINEOPLASTIC AGENT; HYPOXIA ACTIVATED PRODRUG; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; PRODRUG; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER RESISTANCE; CELL HYPOXIA; CELL INFILTRATION; CLINICAL OUTCOME; DRUG DELIVERY SYSTEM; EXTRAVASATION; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; HYPOXIA; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA; MACROPHAGES; NANOMEDICINE; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85015960063     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.03.013     Document Type: Review

References (162)

1. [1] Cancer Research UK, Cancerstats - Terminology and Calculations. 2013, Cancer Research UK (Accessed: September 2016). Available from: www.cruk.org/cancerstats.
2. [2] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
3. [3] Hockenbery, D., et al. The Warburg effect and beyond: metabolic dependencies for cancer cells. Johnson, D.E., (eds.) Cell Death Signaling in Cancer Biology and Treatment, 2013, Springer, New York, 35–51.
4. [4] Meng, X., et al. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev. 31:1–2 (2012), 247–268.
5. [5] Swartz, M.A., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 72:10 (2012), 2473–2480.
6. [6] Maeda, H., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:1–2 (2000), 271–284.
7. [7] Farrell, D., et al. Nanotechnology-based cancer therapeutics–promise and challenge–lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm. Res. 28:2 (2011), 273–278.
8. [8] Borst, P., et al. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:16 (2000), 1295–1302.
9. [9] Coffelt, S.B., Hughes, R., Lewis, C.E., Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 1796:1 (2009), 11–18.
10. [10] Riabov, V., et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front. Physiol., 5, 2014, 75.
11. [11] Patel, A., Sant, S., Hypoxic tumor microenvironment: opportunities to develop targeted therapies. Biotechnol. Adv. 34:5 (2016), 803–812.
12. [12] Thomlinson, R.H., Hypoxia and tumours. J. Clin. Pathol. s3-11:1 (1977), 105–113.
13. [13] Brown, J.M., Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 6:4 (2000), 157–162.
14. [14] Kizaka-Kondoh, S., et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 94:12 (2003), 1021–1028.
15. [15] Casazza, A., et al. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene 33:14 (2014), 1743–1754.
16. [16] Dhani, N., et al. The clinical significance of hypoxia in human cancers. Semin. Nucl. Med. 45:2 (2015), 110–121.
17. [17] Zeng, W., et al. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 356:2 Pt A (2015), 263–267.
18. [18] Bryant, J.L., et al. Targeting hypoxia in the treatment of small cell lung cancer. Lung Cancer 86:2 (2014), 126–132.
19. [19] Marignol, L., et al. Hypoxia in prostate cancer: a powerful shield against tumour destruction?. Cancer Treat. Rev. 34:4 (2008), 313–327.
20. [20] Wilson, W.R., Hay, M.P., Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11:6 (2011), 393–410.
21. [21] Mabjeesh, N.J., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:4 (2003), 363–375.
22. [22] Rapisarda, A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64:19 (2004), 6845–6848.
23. [23] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:1 (2014), 49–61.
24. [24] Chen, W.-H., et al. Mesoporous silica-based versatile theranostic nanoplatform constructed by layer-by-layer assembly for excellent photodynamic/chemo therapy. Biomaterials 117 (2017), 54–65.
25. [25] Liu, Y., et al. Hypoxia induced by upconversion-based photodynamic therapy: towards highly effective synergistic bioreductive therapy in tumors. Angew. Chem. 127:28 (2015), 8223–8227.
26. [26] Chouaib, S., et al. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 3 (2012), 1–21.
27. [27] Onnis, B., Rapisarda, A., Melillo, G., Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 13:9A (2009), 2780–2786.
28. [28] Semenza, G.L., Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33:4 (2012), 207–214.
29. [29] Wang, R., Zhou, S., Li, S., Cancer therapeutic agents targeting hypoxia-inducible factor-1. Curr. Med. Chem. 18:21 (2011), 3168–3189.
30. [30] Burroughs, S.K., et al. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med. Chem. 5:5 (2013), 553–572.
31. [31] Mabjeesh, N.J., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:9 (2002), 2478–2482.
32. [32] Melillo, G., Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4:9 (2006), 601–605.
33. [33] Pacey, S., et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17:6 (2011), 1561–1570.
34. [34] Ronnen, E.A., et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investig. New Drugs 24:6 (2006), 543–546.
35. [35] Solit, D.B., et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14:24 (2008), 8302–8307.
36. [36] Sun, H.L., et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26:27 (2007), 3941–3951.
37. [37] Albertella, M.R., et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin. Cancer Res. 14:4 (2008), 1096–1104.
38. [38] Greenberger, L.M., et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7:11 (2008), 3598–3608.
39. [39] Jeong, W., et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother. Pharmacol. 73:2 (2014), 343–348.
40. [40] Patnaik, A., et al. EZN-2968, a novel hypoxia-inducible factor-1 {alpha}(HIF-1 {alpha}) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. ASCO Annual Meeting Proceedings, 2009.
41. [41] Terzuoli, E., et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res. 70:17 (2010), 6837–6848.
42. [42] Rapisarda, A., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol. Cancer Ther. 8:7 (2009), 1867–1877.
43. [43] Rapisarda, A., et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64:4 (2004), 1475–1482.
44. [44] Kurzrock, R., et al. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118:24 (2012), 6144–6151.
45. [45] Patnaik, A., et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother. Pharmacol. 71:6 (2013), 1499–1506.
46. [46] Zhang, H., et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. PNAS 105:50 (2008), 19579–19586.
47. [47] Jacoby, J.J., et al. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J. Thorac. Oncol. 5:7 (2010), 940–949.
48. [48] Koh, M.Y., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 7:1 (2008), 90–100.
49. [49] Shibata, T., Giaccia, A.J., Brown, J.M., Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7:6 (2000), 493–498.
50. [50] Patterson, A.V., et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 9:14 (2002), 946–954.
51. [51] Hsiao, H.T., et al. Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncol. Rep. 32:2 (2014), 723–729.
52. [52] Sun, X., et al. Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy. Cancer Gene Ther. 17:8 (2010), 532–540.
53. [53] Guise, C.P., et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin. J. Cancer 33:2 (2014), 80–86.
54. [54] Brown, J.M., Wilson, W.R., Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4:6 (2004), 437–447.
55. [55] Bedikian, A.Y., et al. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann. Oncol. 8:4 (1997), 363–367.
56. [56] von Pawel, J., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18:6 (2000), 1351–1359.
57. [57] Ltd, T., Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer. 2014, National Library of Medicine (US), Bethesda (MD) ClinicalTrials.gov (Internet).
58. [58] DiSilvestro, P.A., et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J. Clin. Oncol. 32:5 (2014), 458–464.
59. [59] Aghajanian, C., et al. Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol. Oncol. 67:2 (1997), 127–130.
60. [60] Marcu, L., Olver, I., Tirapazamine: from bench to clinical trials. Curr. Clin. Pharmacol. 1:1 (2006), 71–79.
61. [61] Hicks, K.O., et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16:20 (2010), 4946–4957.
62. [62] Choudry, G.A., et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br. J. Cancer 85:8 (2001), 1137–1146.
63. [63] Ross, D., Siegel, D., NAD (P) H: quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 382 (2004), 115–144.
64. [64] Schellens, J.H.M., et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J. Natl. Cancer Inst. 86:12 (1994), 906–912.
65. [65] Borad, M.J., et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2014, 1474–1481.
66. [66] Meng, F., et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol. Cancer Ther. 11:3 (2012), 740–751.
67. [67] Sun, J.D., et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer Res. 18:3 (2012), 758–770.
68. [68] Weiss, G.J., et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 17:9 (2011), 2997–3004.
69. [69] Guise, C.P., et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70:4 (2010), 1573–1584.
70. [70] Guise, C.P., et al. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol. Pharmacol. 81:1 (2012), 31–40.
71. [71] Konopleva, M., et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 7 (2015), 927–934.
72. [72] McKeage, M.J., et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer, 11, 2011, 432.
73. [73] Singleton, R.S., et al. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res. 69:9 (2009), 3884–3891.
74. [74] McKeown, S.R., et al. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer 72:1 (1995), 76–81.
75. [75] Patterson, L.H., et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer 82:12 (2000), 1984–1990.
76. [76] Liu, Q., et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother. Pharmacol. 69:6 (2012), 1487–1498.
77. [77] Pharmaceuticals, T., Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma. 2012, National Library of Medicine (US), Bethesda (MD) ClinicalTrials.gov (Internet).
78. [78] Pharmaceuticals, T., Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer. 2014, National Library of Medicine (US), Bethesda (MD) ClinicalTrials.gov (Internet).
79. [79] Patterson, A.V., et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 13:13 (2007), 3922–3932.
80. [80] Hu, C.M., Zhang, L., Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83:8 (2012), 1104–1111.
81. [81] Singh, M., Manikandan, S., Kumaraguru, A., Nanoparticles: a new technology with wide applications. Res. J. Nanosci. Nanotechnol. 1:1 (2011), 1–11.
82. [82] Reddy, S.B., Williamson, S.K., Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs 18:1 (2009), 77–87.
83. [83] Chen, J.J., et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 23:5 (2005), 953–964.
84. [84] Geiser, M., Update on macrophage clearance of inhaled micro- and nanoparticles. J. Aerosol. Med. Pulm. Drug Deliv. 23:4 (2010), 207–217.
85. [85] Ahsan, F., et al. Targeting to macrophages: role of physicochemical properties of particulate carriers–liposomes and microspheres–on the phagocytosis by macrophages. J. Control. Release 79:1–3 (2002), 29–40.
86. [86] Ruffell, B., Affara, N.I., Coussens, L.M., Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33:3 (2012), 119–126.
87. [87] Allavena, P., et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222 (2008), 155–161.
88. [88] Vinay, D.S., et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35:Suppl (2015), S185–S198.
89. [89] Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11:10 (2010), 889–896.
90. [90] Lamagna, C., Aurrand-Lions, M., Imhof, B.A., Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 80:4 (2006), 705–713.
91. [91] Mantovani, A., et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25:3 (2006), 315–322.
92. [92] Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141:1 (2010), 39–51.
93. [93] Solinas, G., et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86:5 (2009), 1065–1073.
94. [94] Hagemann, T., et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205:6 (2008), 1261–1268.
95. [95] Hao, N.B., et al. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012 (2012), 1–11.
96. [96] Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6 (2014), 1–13.
97. [97] Quatromoni, J.G., Eruslanov, E., Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am. J. Transl. Res. 4:4 (2012), 376–389.
98. [98] Fidler, I.J., Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res. 34:5 (1974), 1074–1078.
99. [99] Gorelik, E., et al. Augmentation of metastasis formation by thioglycollate-elicited macrophages. Int. J. Cancer 29:5 (1982), 575–581.
100. [100] Dong-Le Bourhis, X., et al. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int. J. Cancer 71:1 (1997), 42–48.
101. [101] Hagemann, T., et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25:8 (2004), 1543–1549.
102. [102] Kelly, C., Jefferies, C., Cryan, S.-A., Targeted liposomal drug delivery to monocytes and macrophages. J. Drug. Deliv. 2011 (2011), 1–11.
103. [103] Soma, C.E., et al. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Release 68:2 (2000), 283–289.
104. [104] Alahari, S.V., Dong, S., Alahari, S.K., Are macrophages in tumors good targets for novel therapeutic approaches?. Mol. Cell 38:2 (2015), 95–104.
105. [105] Zhan, X., et al. Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Biomaterials 35:38 (2014), 10046–10057.
106. [106] Movahedi, K., et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 72:16 (2012), 4165–4177.
107. [107] Yu, S.S., et al. Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol. Pharm. 10:3 (2013), 975–987.
108. [108] Zhu, S., et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol. Pharm. 10:9 (2013), 3525–3530.
109. [109] Ries, C.H., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25:6 (2014), 846–859.
110. [110] Luo, Y., et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116:8 (2006), 2132–2141.
111. [111] Huang, Z., et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J. Control. Release 158:2 (2012), 286–292.
112. [112] Hong, H.Y., et al. Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis. J. Cell. Mol. Med. 12:5B (2008), 2003–2014.
113. [113] Roth, F., et al. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 72:6 (2012), 1373–1383.
114. [114] Allavena, P., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65:7 (2005), 2964–2971.
115. [115] Baay, M., et al. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin. Dev. Immunol. 2011 (2011), 1583–1584.
116. [116] Panni, R.Z., Linehan, D.C., DeNardo, D.G., Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy 5:10 (2013), 1075–1087.
117. [117] Tang, X., et al. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 138:2 (2013), 93–104.
118. [118] Banciu, M., et al. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 10:2 (2008), 108–117.
119. [119] Schiffelers, R.M., et al. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7:2 (2005), 118–127.
120. [120] Zhao, G., Rodriguez, B.L., Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int. J. Nanomedicine 8 (2013), 61–71.
121. [121] Weisser, S.B., van Rooijen, N., Sly, L.M., Depletion and reconstitution of macrophages in mice. J. Vis. Exp., 66, 2012, 4105.
122. [122] Satoh, T., et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res. 63:22 (2003), 7853–7860.
123. [123] Jones, B.W., et al. Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukoc. Biol. 69:6 (2001), 1036–1044.
124. [124] Murphy, B.S., et al. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 61:3 (2008), 554–560.
125. [125] Lewis, C.E., Pollard, J.W., Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:2 (2006), 605–612.
126. [126] Almouazen, E., et al. Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages. Int. J. Pharm. 430:1–2 (2012), 207–215.
127. [127] Al-Hallak, K.M., et al. Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?. Eur. J. Pharm. Biopharm. 76:1 (2010), 112–119.
128. [128] Edin, S., et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One, 7(10), 2012, e47045.
129. [129] Ono, M., Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 99:8 (2008), 1501–1506.
130. [130] Lewis, C., Murdoch, C., Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 167:3 (2005), 627–635.
131. [131] Thambi, T., et al. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials 35:5 (2014), 1735–1743.
132. [132] Liu, X.Q., et al. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Mol. Pharm. 9:10 (2012), 2863–2874.
133. [133] Quan, S., et al. Galactose-based thermosensitive nanogels for targeted drug delivery of iodoazomycin arabinofuranoside (IAZA) for theranostic management of hypoxic hepatocellular carcinoma. Biomacromolecules 16:7 (2015), 1978–1986.
134. [134] Poon, Z., et al. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 5:6 (2011), 4284–4292.
135. [135] Meng, H., et al. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 132:36 (2010), 12690–12697.
136. [136] Dong, J., Xue, M., Zink, J.I., Functioning of nanovalves on polymer coated mesoporous silica nanoparticles. Nano 5:21 (2013), 10300–10306.
137. [137] Qian, C., et al. Light-activated hypoxia-responsive nanocarriers for enhanced anticancer therapy. Adv. Mater. 28:17 (2016), 3313–3320.
138. [138] Muthana, M., et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 71:5 (2011), 1805–1815.
139. [139] Vinogradov, S., Warren, G., Wei, X., Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (London) 9:5 (2014), 695–707.
140. [140] Choi, M.R., et al. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7:12 (2007), 3759–3765.
141. [141] Madsen, S.J., et al. Macrophages as cell-based delivery systems for nanoshells in photothermal therapy. Ann. Biomed. Eng. 40:2 (2012), 507–515.
142. [142] Li, Z., et al. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials 74 (2016), 144–154.
143. [143] Choi, J., et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 33:16 (2012), 4195–4203.
144. [144] Jiang, P.-S., et al. Irradiation enhances the ability of monocytes as nanoparticle carrier for cancer therapy. PLoS One, 10(9), 2015, e0139043.
145. [145] Owen, M.R., et al. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res. 71:8 (2011), 2826–2837.
146. [146] Griffiths, L., et al. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7:3 (2000), 255–262.
147. [147] Muthana, M., et al. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res. 73:2 (2013), 490–495.
148. [148] Huang, W.-C., et al. Monocytic delivery of therapeutic oxygen bubbles for dual-modality treatment of tumor hypoxia. J. Control. Release 220:Part B (2015), 738–750.
149. [149] Huang, W.C., et al. Tumortropic monocyte-mediated delivery of echogenic polymer bubbles and therapeutic vesicles for chemotherapy of tumor hypoxia. Biomaterials 71 (2015), 71–83.
150. [150] Song, M., et al. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano 10:1 (2016), 633–647.
151. [151] Albanese, A., et al. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat. Commun., 4, 2013, 2718.
152. [152] Shi, J., et al. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17:1 (2017), 20–37.
153. [153] Sharpless, N.E., Depinho, R.A., The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5:9 (2006), 741–754.
154. [154] Danhier, F., To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?. J. Control. Release 244:Part A (2016), 108–121.
155. [155] Choi, S.Y., et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv. Drug Deliv. Rev. 79–80 (2014), 222–237.
156. [156] Hare, J.I., et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv. Drug Deliv. Rev. 108 (2017), 25–38.
157. [157] Chatterjee, D.K., Diagaradjane, P., Krishnan, S., Nanoparticle-mediated hyperthermia in cancer therapy. Ther. Deliv. 2:8 (2011), 1001–1014.
158. [158] Kobayashi, H., Watanabe, R., Choyke, P.L., Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics 4:1 (2013), 81–89.
159. [159] Sun, X., et al. The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. Int. J. Hyperth. 26:3 (2010), 224–231.
160. [160] Theek, B., et al. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J. Control. Release 231 (2016), 77–85.
161. [161] De Palma, M., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9:6 (2003), 789–795.
162. [162] Lewis, C.E., De Palma, M., Naldini, L., Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 67:18 (2007), 8429–8432.